Drug Profile
Research programme: neurological disorder therapies - Evotec SE/Merck
Latest Information Update: 27 Sep 2019
Price :
$50
*
At a glance
- Originator Evotec AG; Merck KGaA
- Developer Evotec SE; Merck KGaA
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Neurological-disorders in Germany
- 23 Nov 2010 Early research in Neurological disorders in Germany (unspecified route)